ThromboGenics, Novartis sales and marketing update

ThromboGenics said Novartis' Alcon Inc. ophthalmic unit launched Jetrea ocriplasmin in Canada to treat symptomatic vitreomacular adhesion, a precursor to vitreomacular traction (VMT). Alcon said the...